Photodynamic Therapy Combined With a Self-expandable Radioactive Particle-loaded Biliary Stent for Unresectable Extrahepatic Cholangiocarcinoma (Photodynamic T)
A Clinical Study on the Application Value of Photodynamic Therapy Combined With a Self-expandable Radioactive Particle-loaded Biliary Stent in Unresectable Extrahepatic Cholangiocarcinoma
This is a prospective, single-arm, interventional clinical study. The purpose of this study is to evaluate the clinical efficacy and safety of Photodynamic Therapy (PDT) combined with a self-expandable radioactive particle-loaded biliary stent in patients with unresectable extrahepatic cholangiocarcinoma.
Patients diagnosed with extrahepatic cholangiocarcinoma who are unable to undergo surgical resection will be enrolled. After initial percutaneous transhepatic cholangial drainage (PTCD) to improve liver function, patients will receive an intravenous injection of a photosensitizer (Hematoporphyrin, 3 mg/kg). Approximately 48-72 hours later, PDT will be performed under DSA guidance (1-2 sessions). Subsequently, a self-expandable biliary stent loaded with Iodine-125 radioactive particles will be implanted into the stricture to maintain biliary patency and provide local brachytherapy.
The primary outcome is tumor response or biliary patency evaluated by RECIST v1.1. Secondary outcomes include overall survival, stent patency duration, changes in liver function and tumor markers, and incidence of adverse events. This study aims to provide a new, effective treatment strategy for unresectable extrahepatic cholangiocarcinoma.
研究概览
地位
条件
详细说明
Background: Extrahepatic cholangiocarcinoma is often diagnosed at an advanced stage, precluding curative surgery. Traditional treatments like chemotherapy and radiotherapy have limited efficacy. Photodynamic therapy (PDT) is a minimally invasive local treatment that can destroy tumor cells, but its effective depth is limited (4-6 mm), which may lead to rapid tumor progression or recurrent biliary obstruction. The self-expandable radioactive particle-loaded biliary stent not only provides mechanical biliary drainage but also delivers continuous local brachytherapy (Iodine-125) to inhibit tumor growth. This study proposes that combining PDT with this radioactive stent may provide synergistic effects, prolonging stent patency and improving survival for patients with unresectable extrahepatic cholangiocarcinoma.
Study Design: Prospective, single-arm, interventional clinical study.
Procedures:
PTCD will be performed first to relieve jaundice and improve liver function.
A skin test for photosensitizer allergy will be conducted. If negative, Hematoporphyrin (3mg/kg) will be administered intravenously.
48-72 hours later, DSA-guided biliary tumor biopsy and PDT will be performed (1-2 sessions depending on tolerance).
A self-expandable biliary stent loaded with Iodine-125 particles will be implanted into the stricture after balloon dilation. The drainage tube will be kept for 1-2 weeks post-operation and then removed.
Follow-up: Patients will be followed up every 3-4 weeks initially, and then every 3 months after stabilization (up to 2 years) to monitor tumor response, survival, stent patency, liver function, and adverse events.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Wenlong Zhai, MD
- 电话号码:+86-371-66913095
- 邮箱:fcczhaiwl@zzu.edu.cn
学习地点
-
-
Henan
-
Zhengzhou、Henan、中国、450052
- 招聘中
- The First Affiliated Hospital of Zhengzhou University
-
接触:
- Wenlong Zhai, MD
- 电话号码:+86-371-66913095
- 邮箱:fcczhaiwl@zzu.edu.cn
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 18 years, male or female.
Histologically, cytologically, or radiologically confirmed extrahepatic cholangiocarcinoma.
Poor cardiopulmonary or renal function, unable to tolerate surgical resection.
Extensive tumor invasion, unable to achieve complete surgical resection.
Unable to tolerate surgery due to age or other factors.
Patients who refuse surgical treatment.
Participants voluntarily join the study, sign the informed consent form, have good compliance, and cooperate with follow-up.
Exclusion Criteria:
- Allergic to photosensitizers.
Severe liver dysfunction, hepatic encephalopathy, refractory ascites, or hepatorenal syndrome.
Severe coagulation disorders that cannot be corrected.
Active biliary tract infection.
Severe renal insufficiency.
Cachexia with an expected survival of less than 3 months.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Experimental: PDT combined with Radioactive Stent
Patients will first undergo percutaneous transhepatic cholangial drainage (PTCD). After a negative skin test, Hematoporphyrin (3mg/kg) will be injected intravenously. 48-72 hours later, Photodynamic Therapy (PDT) will be performed under DSA guidance. Subsequently, a self-expandable biliary stent loaded with Iodine-125 radioactive particles will be implanted. |
Intravenous injection of photosensitizer at a dose of 3mg/kg before PDT. Implantation of a biliary stent loaded with Iodine-125 radioactive particles for biliary drainage and local brachytherapy. DSA-guided biliary tumor biopsy and photodynamic laser irradiation (1-2 sessions). Initial biliary drainage to improve liver function and reduce infection risk before PDT. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Tumor response and biliary patency evaluated by RECIST v1.1
大体时间:From baseline up to 24 months
|
Tumor response will be assessed by RECIST v1.1 using upper abdominal contrast-enhanced MRI or CT. Biliary patency will be evaluated based on imaging and liver function tests (e.g., total, direct, and indirect bilirubin). |
From baseline up to 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:From enrollment up to 24 months
|
Time from enrollment to death from any cause. |
From enrollment up to 24 months
|
|
Duration of stent patency
大体时间:From stent implantation up to 24 months
|
Time from stent implantation to stent occlusion or dysfunction. |
From stent implantation up to 24 months
|
|
Incidence of adverse events and complications
大体时间:From baseline up to 24 months
|
Incidence and severity of adverse events (e.g., biliary perforation, infection, cholangitis, photosensitivity) evaluated according to CTCAE v5.0. |
From baseline up to 24 months
|
合作者和调查者
赞助
调查人员
- 首席研究员:Zhai, MD、The First Affiliated Hospital of Zhengzhou University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.